We are analyzing https://link.springer.com/article/10.1007/bf01833338.

Title:
Interference of the IGF system as a strategy to inhibit breast cancer growth | Breast Cancer Research and Treatment
Description:
Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Business & Finance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, growth, breast, google, scholar, pubmed, factor, human, insulinlike, receptor, cells, res, receptors, article, cell, igf, inhibit, tumor, lippman, type, arteaga, igfi, αir, antibodies, access, expression, mol, van, privacy, cookies, content, research, igfii, blockade, binding, endocrinol, cullen, yee, rosen, role, publish, search, treatment, autocrine, monoclonal, inhibition, epidermal, factors, dickson, biol,

Topics {✒️}

growth factor-i-related protein anti-igf receptor antibodies anti-growth factor treatments month download article/chapter receptor signalling pathway steroid hormone antagonists v-ha-ras oncogene block serum-free growth van selm-miltenburg ajp monoclonal antibodies α-ir-1 long-term tissue culture igf neutralizing modalities breast cancer cells related subjects autocrine stimulated growth high-affinity insulin binding human breast cancer epidermal growth factor growth factor-ii growth factor receptor growth factor receptors maximize tumor inhibition breast cancer induced inhibit tumor formation igf-ii present human melanoma cells human breast fibroblasts growth factor action privacy choices/manage cookies potential autocrine role full article pdf diminished tumor growth promote tumor growth de laat sw growth factor secretion growth-promoting activity tumor cell inoculation growth inhibition van wyk jj van zoelen ejj van putten wlj tumor stromal elements mcf-7 cell line european economic area regulation estrogen-induced factors neoplasms potentially dependent breast cancer estrogen-stimulated proliferation igf-ii

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Interference of the IGF system as a strategy to inhibit breast cancer growth
         description:Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.
         datePublished:
         dateModified:
         pageStart:101
         pageEnd:106
         sameAs:https://doi.org/10.1007/BF01833338
         keywords:
            anti-IGF-receptor antibodies
            autocrine growth regulation
            breast cancer cells
            growth inhibition
            IGF-I
            IGF-II
            IGF receptors
            paracrine growth regulation
            therapeutic modalities
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Carlos L. Arteaga
               affiliation:
                     name:Vanderbilt University
                     address:
                        name:Departments of Medicine and Cell Biology, Vanderbilt University, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Interference of the IGF system as a strategy to inhibit breast cancer growth
      description:Experimental evidence suggests that human breast cancer cells can be regulated by the IGF-I and IGF-II present in the tumor stromal elements and/or by the endogenous tumor cell IGF-II in a paracrine or autocrine fashion. Thus, blockade of the receptor signalling pathway could lead to diminished tumor growth. Blockade of the type I IGF receptor by a monoclonal antibody (αIR3) has been used as a strategy to demonstrate the importance of the IGF pathway. Although αIR3 could not block serum-free growth of breast cancer cell lines, it could inhibit anchorage independent growth in most cell lines in the presence of serum. In vivo, αIR3 administered at the time of tumor cell inoculation could inhibit MDA-MB-231 tumor formation in athymic mice; however, inhibition of established tumors was not seen. Moreover, αIR3 could not inhibit tumor formation of the MCF-7 cell line in vivo. These results suggest that blockade of the type I IGF receptor can inhibit the growth of some breast cancer cells both in vitro and in vivo. Future anti-growth factor strategies include the combination of anti-IGF receptor antibodies with IGF neutralizing modalities, the dual blockade of growth factor receptors (epidermal growth factor receptor and type I IGF receptor), and combinations of steroid hormone antagonists and anti-growth factor treatments to maximize tumor inhibition.
      datePublished:
      dateModified:
      pageStart:101
      pageEnd:106
      sameAs:https://doi.org/10.1007/BF01833338
      keywords:
         anti-IGF-receptor antibodies
         autocrine growth regulation
         breast cancer cells
         growth inhibition
         IGF-I
         IGF-II
         IGF receptors
         paracrine growth regulation
         therapeutic modalities
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Carlos L. Arteaga
            affiliation:
                  name:Vanderbilt University
                  address:
                     name:Departments of Medicine and Cell Biology, Vanderbilt University, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:22
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Vanderbilt University
      address:
         name:Departments of Medicine and Cell Biology, Vanderbilt University, Nashville, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Carlos L. Arteaga
      affiliation:
            name:Vanderbilt University
            address:
               name:Departments of Medicine and Cell Biology, Vanderbilt University, Nashville, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Departments of Medicine and Cell Biology, Vanderbilt University, Nashville, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(83)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.66s.

LINK . SPRINGER . COM {}